JV Biolabs
JV Biolabs specializes in developing and utilizing human cell, tissue, and organ culture models, as well as pre-clinical models, to provide efficacy and safety data on compounds during pre-clinical and early clinical stages of development. The company offers advanced models for studying inflammatory and hyperplastic skin diseases, fibrosis, tumor biology, kidney, liver, and metabolic diseases, and more, supporting drug development and safety assessments.
Industries
Nr. of Employees
small (1-50)
Services
Primary and established cell line culture, long-term maintenance, dose–response testing, generation of conditioned supernatants and development of client-specific cell culture models for drug screening and mechanistic studies.
Ex vivo maintenance and treatment of human skin (healthy, aged, photodamaged, psoriatic, diabetic) for assessment of toxicity, hyperplasia, barrier function, collagen turnover, MMP activity, immune responses and molecular profiling.
Transplantation of human psoriatic skin onto immunodeficient mice for preclinical evaluation of anti-psoriatic agents, allowing assessment of clinical changes, histology, immunohistology and cytokine/growth factor modulation under topical or systemic dosing.
Established rodent model used for preclinical assessment of retinoids and anti-acne activity, enabling simultaneous evaluation of efficacy, inflammation, irritation and systemic toxicity for topical and systemic agents.
Acute and chronic vascular injury models with primary human endothelial cells and established lines, cytokine/integrin/cell-surface marker characterization and assessment of angiogenic, apoptotic and drug-induced vascular toxicity mechanisms.
In vivo rodent models for nephrotoxicity, diabetes-related renal injury, vasculitis and glomerulonephritis combined with human and rodent renal cell cultures and ELISA/clinical pathology monitoring of renal biomarkers.
Primary and established cell line culture, long-term maintenance, dose–response testing, generation of conditioned supernatants and development of client-specific cell culture models for drug screening and mechanistic studies.
Ex vivo maintenance and treatment of human skin (healthy, aged, photodamaged, psoriatic, diabetic) for assessment of toxicity, hyperplasia, barrier function, collagen turnover, MMP activity, immune responses and molecular profiling.
Transplantation of human psoriatic skin onto immunodeficient mice for preclinical evaluation of anti-psoriatic agents, allowing assessment of clinical changes, histology, immunohistology and cytokine/growth factor modulation under topical or systemic dosing.
Established rodent model used for preclinical assessment of retinoids and anti-acne activity, enabling simultaneous evaluation of efficacy, inflammation, irritation and systemic toxicity for topical and systemic agents.
Acute and chronic vascular injury models with primary human endothelial cells and established lines, cytokine/integrin/cell-surface marker characterization and assessment of angiogenic, apoptotic and drug-induced vascular toxicity mechanisms.
In vivo rodent models for nephrotoxicity, diabetes-related renal injury, vasculitis and glomerulonephritis combined with human and rodent renal cell cultures and ELISA/clinical pathology monitoring of renal biomarkers.
Expertise Areas
- Preclinical efficacy and safety testing
- Human organotypic skin models
- Dermatology and inflammatory skin disease
- Fibrosis and wound healing research
Key Technologies
- Human organ culture
- Xenograft transplantation
- Primary cell culture
- 2D and 3D cell culture